9,394 Shares in QIAGEN N.V. $QGEN Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC purchased a new stake in QIAGEN N.V. (NYSE:QGEN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 9,394 shares of the company’s stock, valued at approximately $454,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Exchange Traded Concepts LLC grew its position in QIAGEN by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock valued at $716,000 after acquiring an additional 395 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of QIAGEN during the 1st quarter valued at approximately $31,000. Walleye Trading LLC increased its position in QIAGEN by 14.6% during the 1st quarter. Walleye Trading LLC now owns 7,367 shares of the company’s stock worth $296,000 after purchasing an additional 936 shares in the last quarter. GAMMA Investing LLC lifted its stake in QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after purchasing an additional 1,425 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its stake in QIAGEN by 30.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company’s stock valued at $396,000 after purchasing an additional 2,290 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of QIAGEN from a “buy” rating to a “hold” rating in a report on Friday. Bank of America boosted their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a “buy” rating in a research report on Thursday, June 26th. Barclays set a $53.00 target price on QIAGEN and gave the company an “overweight” rating in a research report on Thursday. UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, Cowen reaffirmed a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $49.40.

QIAGEN Price Performance

Shares of QGEN opened at $46.99 on Tuesday. The business has a 50-day moving average of $47.35 and a 200-day moving average of $45.37. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The company has a market capitalization of $10.45 billion, a price-to-earnings ratio of 27.76, a price-to-earnings-growth ratio of 2.47 and a beta of 0.66. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88.

QIAGEN (NYSE:QGEN) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same quarter in the prior year, the firm posted $0.55 EPS. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts anticipate that QIAGEN N.V. will post 2.26 earnings per share for the current year.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.